Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ergonex Pharma granted orphan designation for hypertension drug
Terguride is currently being evaluated for pulmonary arterial hypertension (PAH) in a pivotal Phase II trial in Europe. Rudolf Reiter, CEO of Ergonex Pharma, said: “The FDA’s grant
Terguride is currently being evaluated for pulmonary arterial hypertension (PAH) in a pivotal Phase II trial in Europe. Rudolf Reiter, CEO of Ergonex Pharma, said: “The FDA’s grant
This is claimed to be the longest duration of sustained neutralizing antibody levels observed against both virus types 16 and 18 with a cervical cancer vaccine to date.
Baruch Elad, chairman of the Israeli Society for Sleep Research at the Israel Medical Association, said: “Provigil is activated approximately 8-12 hours after medicine intake. It helps maintain
The study, COR-0002 trial, is a single-blind, open-label, single-center, cross-over pilot study where subjects underwent coronary balloon occlusion, with and without oxygenated HBOC-201. The primary objective of the
As announced earlier, shareholders of Hunter-Fleming now hold 3.1% in Newron. Italy based Newron Pharmaceuticals is a biopharmaceutical company focused on novel therapies for diseases of the central
The double-blind, placebo-controlled G301 study has examined the safety and efficacy of Pollinex Quattro in the treatment of seasonal allergic rhino-conjunctivitis (SAR) caused by grass pollen. The study
Under the agreement, Chugai will co-develop the compound with Taisho and co-market it with Taisho Toyama Pharmaceutical, a subsidiary of Taisho. Chugai will receive an upfront fee and
R7128 is being developed through the company’s collaboration with Roche. The purpose of this four-week study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of R7128
This 500-patient safety trial is the third of three Phase III studies, planned to enroll a total of 1,500 patients, to define the role of cetrorelix in the
This new orphan drug designation builds on the previously granted designation to Alimentary Health for pediatric Crohn’s disease. The pediatric population is defined as patients who are aged